產品名稱：Leishmania infantum IgG ELISA
產    地：Demeditec 
產品貨號：DEIG0310
產品規(guī)格：96 Tests
產品說明：
Special remarks:
INTENDED USE
The Demeditec Leishmania ELISA is intended for the qualitative determination of antibodies against Leishmania infantum in human serum or plasma (citrate).
INTRODUCTION
Leishmania are protozoa belonging to the family trypanosomatidae. The parasites exist in two forms:
the promastigotes in the midgut of the vector insect, and the amastigotes within the phagolysosomes of macrophages in their mammalian hosts. In the macrophages they live as round, non-motile amastigotes (3-7 mm in diameter). The macrophages are ingested by the sandfly during blood-meal and the
amastigotes are released into their stomach. Almost immediately the amastigotes transform in to the motile, elongated (10-20µm), flagellate promastigote form, which migrate to the alimentary tract of the fly  and  after  multiplication  move  forward  to  the  salivary  glands  of  the  insect.
Leishmaniases  are  a globally widespread group of parasitic diseases; the “type” is determined by the primary location of the macrophages that are infected. In humans four different forms of Leishmaniasis with a broad range of clinical  manifestations  are  present;  all  can  have  devasting  consequences.  Leishmaniasis  currently affects some 12 million people in  88 countries, all  but 16 of which are  in the developing  world. It is estimated  that  350  million  people  are  exposed  to  the  risk  of  infection  by  the  different  species  of Leishmania parasite; the annual incidence of new cases is about 2 million (1-1.5 million cases of CL, 500,000  cases  of  VL).  Visceral  leishmaniasis  (VL)  is  the most  severe  form  of  the  disease,  which,  if untreated, has a mortality rate of almost 100%. Like many other tropical diseases, the leishmaniases are related to  economic development and man-made environmental changes,  which  increase exposure  to  the  sandfly  vector.  The  geographical  distribution  is  limited  by  the  distribution  of  the  sandfly.
AIDS and other immunosuppressive conditions increase the risk of Leishmania infected people developing  visceral  illness  (VL).  Leishmania/HIV  co-infections  are  considered  to  be  a  real  “emerging  disease”, especially in south-western Europe, where 25-70% of ***** VL cases are related to HIV infec-tion, and 1.5-9.5% of AIDS cases suffer from newly acquired or reactivated VL. Intravenous drug users have been identified as the main population at risk.
上海玉博生物技術有限公司在為生命科學領域提供豐富的產品與信息資源方面處于國內**地位，公司提供的產品涵蓋了二十多個國家近五十萬種產品，而且產品的數量與信息在不斷的增長和更新，公司提供的產品能夠使生命科學工作者加快對生物化學，分子生物學，細胞生物學以及蛋白質組學研究的認知，以及分子診斷和臨床醫(yī)學領域的應用。

產品留言

標題

聯系人

聯系電話

內容

驗證碼

點擊換一張

注：1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請您留下您的詳細聯系方式!